PMID- 31305441
OWN - NLM
STAT- MEDLINE
DCOM- 20190722
LR  - 20231213
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 28
DP  - 2019 Jul
TI  - The clinical significance of PYCR1 expression in renal cell carcinoma.
PG  - e16384
LID - 10.1097/MD.0000000000016384 [doi]
LID - e16384
AB  - Pyrroline-5-carboxylate reductase 1 (PYCR1) is an enzyme involved in cell 
      metabolism and is upregulated in cancer. However, the correlations of PYCR1 
      expression with the clinicopathological features and prognosis of renal cell 
      carcinoma (RCC) remain unclear. The purpose of this study was to identify the 
      expression of PYCR1 and its clinical relevance in RCC patients.PYCR1 mRNA 
      expression differences between RCC and the adjacent normal renal tissues were 
      assessed using the Cancer Genome Atlas database (TCGA). Subsequently, the 
      expression of PYCR1 mRNA and protein were evaluated by quantitative real-time 
      polymerase chain reaction, Western blot, and immunochemistry using 30 paired 
      frozen samples of RCC and the adjacent normal renal tissues. The protein 
      expression of PYCR1 was evaluated by immunostaining formalin-fixed, 
      paraffin-embedded sections of RCC samples from 96 patients who underwent radical 
      nephrectomy, and its relationship with clinical features were analyzed. Nonpaired 
      t tests were used to statistically analyze the differences between the 2 groups. 
      Cox univariable and multivariable analyses of overall survival (OS) among RCC 
      patients were performed.The expression of PYCR1 mRNA was significantly 
      upregulated in RCC tissues compared to adjacent normal renal tissues in the TCGA 
      database (P < .01). The area under the receiver operating characteristic curve 
      value was 0.748. The expression of PYCR1 mRNA and protein was significantly 
      upregulated in RCC compared with that in paired normal renal tissues (P < .01). 
      Higher PYCR1 levels were associated with metastasis (P < .01). Kaplan-Meier 
      survival curves indicated that higher PYCR1 expression was correlated with poorer 
      OS. Therefore, PYCR1 may act as a novel prognostic marker and therapeutic target 
      in the diagnosis and treatment of RCC.
FAU - Weijin, Fu
AU  - Weijin F
AD  - Department of Urology, The First Affiliated Hospital of GuangXi Medical 
      University, NanNing.
FAU - Zhibin, Xie
AU  - Zhibin X
AD  - Department of Urology, The First Affiliated Hospital of GuangXi Medical 
      University, NanNing.
FAU - Shengfeng, Zheng
AU  - Shengfeng Z
AD  - Department of Urology, The First Affiliated Hospital of GuangXi Medical 
      University, NanNing.
FAU - Xiaoli, Yang
AU  - Xiaoli Y
AD  - Scientific Research Center, GuiLin Medical University, GuiLin.
FAU - Qijian, Ding
AU  - Qijian D
AD  - Department of Urology, The First Affiliated Hospital of GuangXi Medical 
      University, NanNing.
FAU - Jiayi, Liu
AU  - Jiayi L
AD  - Department of Pathology, The First Affiliated Hospital of Guang, Xi Medical 
      University, NanNing, GuangXi, China.
FAU - Qiumei, Liang
AU  - Qiumei L
AD  - Department of Urology, The First Affiliated Hospital of GuangXi Medical 
      University, NanNing.
FAU - Yilong, Chen
AU  - Yilong C
AD  - Department of Urology, The First Affiliated Hospital of GuangXi Medical 
      University, NanNing.
FAU - Hua, Mi
AU  - Hua M
AD  - Department of Urology, The First Affiliated Hospital of GuangXi Medical 
      University, NanNing.
FAU - Deyun, Liu
AU  - Deyun L
AD  - Department of Urology, The First Affiliated Hospital of GuangXi Medical 
      University, NanNing.
FAU - Jiwen, Cheng
AU  - Jiwen C
AD  - Department of Urology, The First Affiliated Hospital of GuangXi Medical 
      University, NanNing.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - EC 1.5.1.- (Pyrroline Carboxylate Reductases)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Renal Cell/*enzymology/mortality/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kidney/enzymology/pathology
MH  - Kidney Neoplasms/*enzymology/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Pyrroline Carboxylate Reductases/*metabolism
MH  - RNA, Messenger/metabolism
MH  - Survival Analysis
MH  - delta-1-Pyrroline-5-Carboxylate Reductase
PMC - PMC6641676
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/07/16 06:00
MHDA- 2019/07/23 06:00
PMCR- 2019/07/12
CRDT- 2019/07/16 06:00
PHST- 2019/07/16 06:00 [entrez]
PHST- 2019/07/16 06:00 [pubmed]
PHST- 2019/07/23 06:00 [medline]
PHST- 2019/07/12 00:00 [pmc-release]
AID - 00005792-201907120-00054 [pii]
AID - MD D-18-08452 [pii]
AID - 10.1097/MD.0000000000016384 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Jul;98(28):e16384. doi: 10.1097/MD.0000000000016384.